In a new update for the obesity market, Britain has authorized an oral version of Novo Nordisk’s blockbuster weight-loss medicine Wegovy. The UK approval for Wegovy pill now makes the UK the first European market to make the oral formulation available and joins the United States and the United Arab Emirates in allowing its use.
The Medicines and Healthcare products Regulatory Agency (MHRA) gave this approval, after which eligible patients will have access to a tablet form of Wegovy, offering an alternative to weekly injections.
According to the MHRA, the medicine met regulatory standards for safety, quality, and effectiveness before receiving authorization. The tablet contains semaglutide, the same active ingredient used in injectable Wegovy, and is designed to support weight management alongside a reduced-calorie diet and increased physical activity.
The availability of weight-loss oral pills in the UK is significant for millions of people living with obesity and comes amid growing demand for more convenient treatment options.
Novo Nordisk Weight-Loss Pill Approval Expands Access
Access to the first oral GLP-1 drug in UK may help address a key challenge in obesity treatment.
According to data, around 2.4 million people in the UK used GLP-1 medicines last year, but only about 200,000 received treatment through the National Health Service (NHS) plan. Most patients accessed these medicines privately.
Demand for oral treatment is already substantial. More than 55,000 people have joined its waitlist for the newly approved oral GLP-1 option. The company also estimates that 120,000 to 130,000 patients could begin using oral GLP-1 medicines within the first three months of launch.
Abdal Alvi, Chief Clinical Officer at Simple Online Healthcare, said, “For many people, a tablet may feel more familiar and less daunting than an injection, and oral GLP-1s have the potential to widen access to effective obesity treatment.”
Further Review Pending
Although the UK approval for Wegovy pill is now in place, the medication is not yet available through the NHS.
The National Institute for Health and Care Excellence (NICE) must first evaluate the treatment before determining whether it should be funded for public use. Until then, eligible patients will need private prescriptions to access the medicine.
About The Oral GLP-1 Weight-Loss Drug Wegovy
The newly approved Wegovy weight-loss pill is intended for:
- Adults with obesity and a body mass index (BMI) of 30 or higher
- Adults with a BMI between 27 and 30 who have at least one weight-related health condition
The once-daily tablet contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone involved in appetite regulation. It helps people feel fuller for longer, reduces hunger, and may lower food cravings.
Clinical studies found that patients taking the highest dose achieved approximately 14% to 17% weight loss after 64 weeks, highlighting the treatment’s potential effectiveness in long-term obesity management.
Side Effects & Safe Use Considerations of Wegovy Pill
Patients prescribed the tablet must follow specific instructions to ensure proper absorption. The MHRA advises taking the medicine:
- On an empty stomach after fasting for at least eight hours
- With a small amount of water
- At least 30 minutes before consuming food or drink
The starting dose is 1.5 mg once daily and gradually increases to 25 mg. Patients already using private Wegovy injections may be eligible to transition directly to the tablet formulation.
The most commonly reported side effects of Wegovy include:
- Nausea
- Diarrhoea
- Constipation
- Vomiting
Healthcare professionals emphasize that medication should be combined with nutrition, physical activity, and behavioural support rather than viewed as a standalone solution.
Conclusion
Analysts project the obesity drug market could exceed $100 billion by 2030, making oral treatments an important growth area for the pharmaceutical industry.
The UK approval for Wegovy pill represents a major milestone for obesity treatment in Europe. By becoming the first to introduce oral GLP-1 weight-loss therapy in the region, regulators have expanded patient choice and created a potential pathway for broader treatment access.
The competition in the global obesity treatment sector is intensifying. Novo Nordisk and Eli Lilly are both investing heavily in oral therapies as companies seek alternatives to injectable medicines. The obesity drug market is projected to exceed $100 billion by 2030, making oral treatments an important growth area for the pharmaceutical industry.
While NHS availability still depends on NICE’s review, the approval in the UK signals growing momentum behind innovative obesity therapies.
